SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
